Source link : https://www.newshealth.biz/health-news/have-the-new-pulmonary-hypertension-drugs-changed-the-game/
In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for WHO group 1 pulmonary hypertension (PH, or PAH) over the course of one […]
Author : News Health
Publish date : 2024-12-29 14:00:00
Copyright for syndicated content belongs to the linked Source.